Navigation Links
Inovio Pharmaceuticals Announces Transition of Avtar Dhillon to Non-Executive Chairman of the Board
Date:7/1/2011

BLUE BELL, Pa., July 1, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Dr. Avtar Dhillon has become non-executive Chairman of the Board of Directors. Dr. Dhillon was initially appointed as Executive Chairman of the Board in 2009 in conjunction with the merger between Inovio Biomedical and VGX Pharmaceuticals with a mandate to provide continuity and strategic guidance during their integration. Dr. Dhillon will now exclusively focus on his role as chairman of the Board of Directors and will no longer have executive responsibilities.

Dr. J. Joseph Kim, Inovio's President and CEO, said: "Avtar has provided strong leadership and support during the integration and build up of Inovio Pharmaceuticals. We look forward to his continued leadership as a non-executive Chairman."  

About Inovio Pharmaceuticals, Inc.

Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. Its SynCon™ vaccines are designed to provide broad cross-strain protection against known as well as newly emergent strains of pathogens such as influenza. These vaccines, in combination with Inovio's proprietary electroporation delivery devices, have been shown to be safe and generate significant immune responses. Inovio clinical programs include three Phase II studies for vaccines treating cervical dysplasia/cancer, hepatitis C virus, and leukemia. Other clinical programs target influenza (preventive) and HIV (preventive and therapeutic). Inovio partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2010, our Form 10-Q for the three months ended March 31, 2011, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

Logo:  http://photos.prnewswire.com/prnh/20110127/LA37605LOGO)

CONTACTS:
Investors: Bernie Hertel, Inovio Pharmaceuticals 858-410-3101 bhertel@inovio.com
Media: Jeff Richardson, Richardson & Associates 805-491-8313 jeff@richardsonglobalpr.com


'/>"/>
SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inovio Pharmaceuticals to Present at Scientific & Industry Conferences
2. Inovio Pharmaceuticals Subsidiary, VGX Animal Health, to Present at VetHealth Global 2011, June 14-17, 2011
3. Inovio Pharmaceuticals to Present at American Society of Gene & Cell Therapy Annual Meeting May 18 - 21, 2011
4. Inovio Pharmaceuticals Market-Leading Intellectual Property Recognized by MDB Capital Award
5. Inovio Pharmaceuticals to Present at Investor Conferences
6. Inovio Pharmaceuticals, Transgene and ChronTech Pharma to Collaborate on Heterologous Prime-Boost Therapeutic Vaccination Against Hepatitis C
7. OncoSec Medical Closes Purchase and License Agreement for Tumor Therapy Technology with Inovio Pharmaceuticals
8. Inovio Pharmaceuticals to Present at Scientific Conferences
9. Inovio Pharmaceuticals Receives U.S. DOD Small Business Innovation Research Grant for Multi-Vaccine DNA Delivery Device Development
10. Inovio Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
11. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Invivotek, LLC, a Genesis Biotechnology Group ® ... pharmacology contract research organization (CRO), announced the completion of ... preclinical research facility in Hamilton, New Jersey ... energy source to reduce costs and lessen the CRO ... Solar Farm follows Invivotek,s recent expansion from a 19,712 ...
(Date:3/24/2017)... -- New England Pediatric Device Consortium (NEPDC) announced Velano ... and in-kind service towards the commercialization of the company,s ... blood draws less traumatic for children could go a ... We,re looking forward to working with Velano Vascular to ... the kids we treat," said Ann-Christine Duhaime , ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets has ... Report" report to their offering. ... This report analyzes the worldwide markets for Dental Implants in ... Canada , Japan , Europe ... , and Rest of World. Annual estimates and forecasts ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... 27, 2017 , ... Sodium determination is consistently becoming more ... expert user knowledge. In a live webinar on April 11th and October 3rd, ... accurate, determination of sodium. , It has long been known that too much ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... with opioids alone responsible for over 33,000 of the 52,404 drug-related deaths in ... Bill (AB) 1512, which proposes a tax on prescription opioids to fund drug ...
(Date:3/25/2017)... PA (PRWEB) , ... March 25, 2017 , ... Getting ... as a public relations partner. , All through the year, Garden Media aims ... press releases, working with key influencers and pitching client’s key messages to ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... which will spark a conversation on the current obstacles facing infection prevention and ... completely preventable deaths caused by these infections. , The print component of ...
(Date:3/24/2017)... ... March 24, 2017 , ... According to a new ... invalid because it does not obey the rules Congress has directed the CBO to ... which the GOP reform would restore. Yet, it estimates a reduction in employer-based coverage ...
Breaking Medicine News(10 mins):